Physician profile
Adria Burrows
NPI 1841298932
$1,188.26
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $60.87 · 2021: $168 · 2022: $263 · 2023: $315 · 2024: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $331.59 | 2019-2022 | |
| Oyster Point Pharma, INC. | $156.24 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $138.75 | 2019 | |
| Apellis Pharmaceuticals, INC. | $125.00 | 2023 | Syfovre |
| Glaukos Corporation | $93.08 | 2022 | |
| Thea Pharma INC. | $87.29 | 2024 | Iyuzeh |
| Abbvie INC. | $83.78 | 2022-2024 | Ozurdex |
| Baxter Healthcare | $40.66 | 2023 | Hillrom - Spot Vision Screener |
| Alcon Vision LLC | $25.87 | 2022-2024 | Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.28 | 2020-2021 | |
| Travere Therapeutics, INC. | $19.95 | 2019-2023 | Cholbam |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biotissue Holdings INC. | $15.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.38 | 2019 | |
| Shire North American Group INC | $13.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adria Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.